Truvestments Capital’s ADMA Biologics ADMA Stock Holding History

Truvestments Capital’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.94K	Buy	+351	New	+$3.2K	﹤0.01%	975
2026 Q1	–	Sell	-158	Closed	-$2.88K	–	1178
2025 Q4	$2.88K	Hold	158	–	–	﹤0.01%	865
2025 Q3	$2.32K	Sell	158 -275	-64%	-$4.71K	﹤0.01%	911
2025 Q2	$7.88K	Hold	433	–	–	﹤0.01%	681
2025 Q1	$8.59K	Sell	433 -84	-16%	-$1.45K	﹤0.01%	681
2024 Q4	$8.87K	Buy	517 +331	+178%	+$6.23K	﹤0.01%	621
2024 Q3	$3.72K	Buy	+186	New	+$2.89K	﹤0.01%	722

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Truvestments Capital's ADMA Position: Q2 2026 in Review

Truvestments Capital opened a new position in ADMA Biologics (ADMA) in Q2 2026: 351 shares worth $2.94K. The stake represents ﹤0.01% of the portfolio and ranks #975 among its holdings. This is a return to the name: Truvestments Capital previously reported a position in ADMA as recently as Q4 2025.

Truvestments Capital first reported a position in ADMA in Q3 2024 and has held it in 7 quarters since. The position peaked at $8.87K in Q4 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Truvestments Capital held 351 shares of ADMA Biologics worth $2.94K as of Q2 2026.
ADMA Biologics was a new Truvestments Capital position in Q2 2026.
ADMA Biologics made up ﹤0.01% of Truvestments Capital's portfolio in Q2 2026, its #975 holding.
Truvestments Capital first reported a position in ADMA Biologics in Q3 2024 and has held it in 7 quarters since.
Truvestments Capital's ADMA Biologics position peaked at $8.87K in Q4 2024.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.